The Comprehensive Guide to Busulfan 60mg Injection In the advanced landscape of hematology and bone marrow transplantation, Busulfan 60mg Injection (6mg/mL) is a critical therapeutic agent. As a premier pharmaceutical exporter from India, Ernest Oncology (a group of Ernest Pharmaceutical Pvt. Ltd.) ensures that this vital conditioning agent is available to healthcare providers and oncology centers in London, New York, Sydney, Johannesburg, and beyond. Product Specifications Brand Name: Ernest-Oncology (Busulfan) Concentration: 60 mg per 10 mL vial (6 mg/mL) Dosage Form: Solution for Injection / Concentrate for Infusion Primary Indication: Conditioning regimen prior to hematopoietic stem cell transplantation (HSCT) Storage: Store under refrigeration at 2Β°C to 8Β°C (36Β°F to 46Β°F); do not freeze. Mechanism of Action: How It Works DNA Cross-Linking: It works by attaching alkyl groups to DNA bases, resulting in the cross-linking of DNA strands. Inhibiting Replication: This process prevents the DNA from uncoiling and replicating, which is essential for cell division. Cellular Myeloablation: By inducing cell death in the bone marrow, it effectively βclearsβ the patient's existing marrow to make room for healthy donor stem cells. Therapeutic Indications & Administration Conditioning Regimen: Used in combination with other drugs (like Cyclophosphamide) to destroy bone marrow and cancer cells before a bone marrow or stem cell transplant. Chronic Myelogenous Leukemia (CML): Specifically indicated for the treatment of CML in preparation for allogeneic transplantation. Administration: * Intravenous Infusion: Must be diluted (usually 10x volume with 0.9% NaCl or 5% Dextrose) and administered over 2 hours via a central venous catheter. Strict Schedule: Typically given every 6 hours for 4 consecutive days (total of 16 doses). Prophylaxis: Patients are often given anti-seizure medication prior to administration, as high doses can lower the seizure threshold. Clinical Side Effects & Safety Profile Hematologic Effects: Profound myelosuppression (low blood counts) is the intended effect but requires careful management of infection and bleeding risks. Gastrointestinal: Nausea, vomiting, diarrhea, and severe mucositis (mouth sores) are common. Hepatic Veno-Occlusive Disease (HVOD): A serious risk characterized by liver enlargement, weight gain, and jaundice. Pulmonary Toxicity: Rare cases of βBusulfan lungβ or pulmonary fibrosis have been reported with long-term or high-dose use. Contraindications: Contraindicated in patients with a history of hypersensitivity to Busulfan. It is known to cause fetal harm; effective contraception is mandatory. Why Source from Ernest Oncology? United Kingdom (London): Supplying cost-effective oncology solutions for specialized transplant units and private hospitals. USA: Delivering bulk supply solutions that meet stringent quality and logistical benchmarks for CML treatment. Australia: Ensuring stable supply through the βSpecial Access Schemeβ (SAS) and professional oncology channels. South Africa: Bridging the gap in the local market with high-tier pharmaceutical exports to support advanced cancer care. π Contact Ernest Oncology β Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] π¦ Business Type: Exporter | Bulk Supplier | Distributor π Websites: www.oncologymedicinesupplier.com www.ernestpharmaceuticals.com www.ernestvision.com www.ernestimpex.com π§ Email: exports@ernestpharmaceuticals.com π² WhatsApp: +91 93599 02383 π Direct Link: https://wa.me/919359902383